Zenith Drugs (NSE:ZENITHDRUG) EBIT: ₹110 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
35 GF Score
Price ₹44.65
! 7 Warning Signs
View Full Analysis

What is Zenith Drugs EBIT?

Zenith Drugs NSE:ZENITHDRUG +2.88% 35 EBIT is ₹110 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 35/100. The stock has 7 warning signs investors should review.

Zenith Drugs's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹110 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zenith Drugs's annualized ROC % for the quarter that ended in Mar. 2026 was 2.38%. Zenith Drugs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zenith Drugs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.37%.

Zenith Drugs  (NSE:ZENITHDRUG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zenith Drugs's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=58.834 * ( 1 - 47.34% )/( (1281.913 + 1316.697)/ 2 )
=30.9819844/1299.305
=2.38 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1652.43 - 365.558 - ( 4.959 - max(0, 804.575 - 1154.36+4.959))
=1281.913

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1875.197 - 555.889 - ( 2.611 - max(0, 940.831 - 1289.638+2.611))
=1316.697

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zenith Drugs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=122.568/( ( (433.832 + max(595.528, 0)) + (468.795 + max(566.842, 0)) )/ 2 )
=122.568/( ( 1029.36 + 1035.637 )/ 2 )
=122.568/1032.4985
=11.87 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(596.207 + 385.126 + 30.621) - (365.558 + 0 + 50.868)
=595.528

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(733.548 + 424.22 + -2.2737367544323E-13) - (555.889 + 0 + 35.037)
=566.842

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zenith Drugs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=109.985/1314.135
=8.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs EBIT Related Terms

Zenith Drugs EBIT Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs EBIT Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 63.53 78.04 152.93 129.72 109.99

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only 63.19 69.60 60.12 48.70 61.28

NSE:ZENITHDRUG vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Drugs EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zenith Drugs's EV-to-EBIT falls into.


NSE:ZENITHDRUG
35GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹110 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹110 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a EBIT of ₹110 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zenith Drugs.
Is Zenith Drugs' EBIT too high?
Zenith Drugs' current EBIT is ₹110 Mil. Overall, Zenith Drugs has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' EBIT compare to ZTS?
Zenith Drugs' EBIT of ₹110 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zenith Drugs. Zenith Drugs's current EBIT is ₹110 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current EBIT of ₹110 Mil. The current EBIT is ₹110 Mil. Zenith Drugs' overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current EBIT is ₹110 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
35GF Score

Get the complete analysis for NSE:ZENITHDRUG

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹44.65
Price